Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.85 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812261 | 0.92 | KDR (1.00) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548912 | 0.91 | KDR (0.84) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548917 | 0.88 | KDR (0.75) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548921 | 0.88 | KDR (0.79) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548926 | 0.88 | KDR (0.73) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548923 | 0.87 | KDR (0.72) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548942 | 0.86 | KDR (0.75) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548941 | 0.86 | KDR (0.77) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548914 | 0.86 | KDR (0.83) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL4548913 | 0.86 | KDR (0.83) | KDRBRAFMAPK14TNNI3KFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885GRM5 2018/4885BRAF 170/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885GRM5 2018/4885BRAF 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.